Literature DB >> 28968297

Solitary Fibrous Tumor of the Vulva: Report of 2 Cases, Including a De Novo Dedifferentiated Solitary Fibrous Tumor Diagnosed After Molecular Demonstration of NAB2-STAT6 Gene Fusion.

Juan C Tardío1, Isidro Machado, Isabel Alemany, M Victoria López-Soto, M Gema Nieto, Antonio Llombart-Bosch.   

Abstract

Solitary fibrous tumor (SFT) is a neoplasm of fibroblastic lineage that has been documented in almost every anatomic location. Vulval SFT is very rare with only 10 cases reported to date. We present 2 additional SFTs located in the vulva, in adult women of 59 and 25 yr of age. The first showed a classic morphology and immunophenotype with uniform and strong STAT6 nuclear expression. The other one was a spindle-cell de novo dedifferentiated SFT with heterogeneous nuclear and cytoplasmic STAT6 staining, which could only be correctly diagnosed after molecular analysis with demonstration of a NAB2-STAT6 gene fusion. This genetic aberration is considered to represent the major pathogenic driver in SFT and is highly specific for this neoplasm. The differential diagnosis of vulval SFT is wide and varies depending on the histologic SFT subtype. Molecular analysis is mandatory for a correct diagnosis in cases without the characteristic histopathologic and immunophenotypical features.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28968297     DOI: 10.1097/PGP.0000000000000464

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  2 in total

Review 1.  A broad ligament solitary fibrous tumor with Doege-Potter syndrome.

Authors:  Sijing Chen; Ying Zheng; Lin Chen; Qihua Yi
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

2.  An abdominal-sacral approach with preoperative embolisation for vulvar solitary fibrous tumour: a case report.

Authors:  Akimasa Takahashi; Hiroki Nishimura; Tsukuru Amano; Mari Deguchi; Fumi Yoshino; Ryo Kasei; Fuminori Kimura; Suzuko Moritani; Takashi Murakami
Journal:  World J Surg Oncol       Date:  2021-03-29       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.